Exelixis Inc Costs and Expenses
Exelixis Inc (EXEL) reported Costs and Expenses of $380.28 million for the 3-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-05
- Exelixis Inc costs and expenses for the quarter ending 2026-07-03 was $380.28M, a 7.22% increase year-over-year.
- Exelixis Inc costs and expenses for the quarter ending 2026-04-03 was $359.47M, a 2.47% decline year-over-year.
- Exelixis Inc costs and expenses for the quarter ending 2026-01-02 was $363.45M, a 9.94% decline year-over-year.
- Exelixis Inc costs and expenses for the quarter ending 2025-10-03 was $361.21M, a 10.47% decline year-over-year.
- Exelixis Inc costs and expenses for fiscal 2026 was $1.45B, a 7.43% decline from fiscal 2025.
- Exelixis Inc costs and expenses for fiscal 2025 was $1.56B, a 5.74% decline from fiscal 2023.
- Exelixis Inc costs and expenses for fiscal 2023 was $1.66B, a 17.72% increase from fiscal 2022.
- Exelixis Inc costs and expenses for fiscal 2022 was $1.41B, a 22.75% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-07-03 | $380.28M 10-Q · filed 2026-08-05 | $739.75M 10-Q · filed 2026-08-05 | $1.10B derived: sum of 3 quarters · filed 2026-08-05 | $1.46B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $359.47M 10-Q · filed 2026-05-05 | $722.92M derived: sum of 2 quarters · filed 2026-05-05 | $1.08B derived: sum of 3 quarters · filed 2026-05-05 | $1.44B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $363.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $724.66M derived: sum of 2 quarters · filed 2026-02-10 | $1.08B derived: sum of 3 quarters · filed 2026-08-05 | $1.45B 10-K · filed 2026-02-10 |
| 2025-10-03 | $361.21M 10-Q · filed 2025-11-04 | $715.90M derived: sum of 2 quarters · filed 2026-08-05 | $1.08B 10-Q · filed 2025-11-04 | $1.49B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $354.69M 10-Q · filed 2026-08-05 | $723.27M 10-Q · filed 2026-08-05 | $1.13B derived: sum of 3 quarters · filed 2026-08-05 | $1.53B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $368.59M 10-Q · filed 2026-05-05 | $772.14M derived: sum of 2 quarters · filed 2026-05-05 | $1.18B derived: sum of 3 quarters · filed 2026-05-05 | $1.54B derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $403.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $807.02M derived: sum of 2 quarters · filed 2026-02-10 | $1.17B derived: sum of 3 quarters · filed 2026-02-10 | $1.56B 10-K · filed 2026-02-10 |
| 2024-09-27 | $403.47M 10-Q · filed 2025-11-04 | $764.77M derived: sum of 2 quarters · filed 2025-11-04 | $1.16B 10-Q · filed 2025-11-04 | $1.56B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $361.30M 10-Q · filed 2025-07-28 | $757.07M 10-Q · filed 2025-07-28 | $1.15B derived: sum of 3 quarters · filed 2026-02-10 | $1.64B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $395.76M 10-Q · filed 2025-05-13 | $793.63M derived: sum of 2 quarters · filed 2026-02-10 | $1.28B derived: sum of 3 quarters · filed 2026-02-10 | $1.68B derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $397.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $887.37M derived: sum of 2 quarters · filed 2026-02-10 | $1.28B derived: sum of 3 quarters · filed 2026-02-10 | $1.66B 10-K · filed 2026-02-10 |
| 2023-09-29 | $489.50M 10-Q · filed 2024-10-29 | $881.50M derived: sum of 2 quarters · filed 2024-10-29 | $1.26B 10-Q · filed 2024-10-29 | $1.73B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $392.00M 10-Q · filed 2024-08-06 | $771.96M 10-Q · filed 2024-08-06 | $1.24B derived: sum of 3 quarters · filed 2025-02-11 | $1.57B derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $379.96M 10-Q · filed 2024-04-30 | $851.95M derived: sum of 2 quarters · filed 2025-02-11 | $1.18B derived: sum of 3 quarters · filed 2025-02-11 | $1.52B derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $472.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $801.12M derived: sum of 2 quarters · filed 2025-02-11 | $1.14B derived: sum of 3 quarters · filed 2025-02-11 | $1.41B 10-K · filed 2025-02-11 |
| 2022-09-30 | $329.13M 10-Q · filed 2023-11-01 | $664.85M derived: sum of 2 quarters · filed 2023-11-01 | $937.58M 10-Q · filed 2023-11-01 | $1.27B derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $335.72M 10-Q · filed 2023-08-01 | $608.46M 10-Q · filed 2023-08-01 | $942.95M derived: sum of 3 quarters · filed 2024-02-06 | $1.22B derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $272.74M 10-Q · filed 2023-05-09 | $607.23M derived: sum of 2 quarters · filed 2024-02-06 | $884.03M derived: sum of 3 quarters · filed 2024-02-06 | $1.15B derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $334.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $611.30M derived: sum of 2 quarters · filed 2024-02-06 | $873.47M derived: sum of 3 quarters · filed 2024-02-06 | $1.15B 10-K · filed 2024-02-06 |
| 2021-10-01 | $276.80M 10-Q · filed 2022-11-01 | $538.97M derived: sum of 2 quarters · filed 2022-11-01 | $813.81M 10-Q · filed 2022-11-01 | $1.06B derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $262.17M 10-Q · filed 2022-08-09 | $537.01M 10-Q · filed 2022-08-09 | $782.76M derived: sum of 3 quarters · filed 2023-02-07 | $1.06B derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $274.84M 10-Q · filed 2022-05-10 | $520.59M derived: sum of 2 quarters · filed 2023-02-07 | $794.26M derived: sum of 3 quarters · filed 2023-02-07 | $978.21M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $245.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $519.43M derived: sum of 2 quarters · filed 2023-02-07 | $703.37M derived: sum of 3 quarters · filed 2023-02-07 | $877.48M 10-K · filed 2023-02-07 |
| 2020-10-02 | $273.67M 10-Q · filed 2021-11-02 | $457.62M derived: sum of 2 quarters · filed 2021-11-02 | $631.72M 10-Q · filed 2021-11-02 | $794.72M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $183.94M 10-Q · filed 2021-08-05 | $358.05M 10-Q · filed 2021-08-05 | $521.04M derived: sum of 3 quarters · filed 2022-02-18 | $677.14M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $174.11M 10-Q · filed 2021-05-06 | $337.10M derived: sum of 2 quarters · filed 2022-02-18 | $493.20M derived: sum of 3 quarters · filed 2022-02-18 | $641.48M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $162.99M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $319.09M derived: sum of 2 quarters · filed 2022-02-18 | $467.38M derived: sum of 3 quarters · filed 2022-02-18 | $598.30M 10-K · filed 2022-02-18 |
| 2019-09-27 | $156.10M 10-Q · filed 2020-11-05 | $304.38M derived: sum of 2 quarters · filed 2020-11-05 | $435.31M 10-Q · filed 2020-11-05 | |
| 2019-06-28 | $148.29M 10-Q · filed 2020-08-06 | $279.21M 10-Q · filed 2020-08-06 | ||
| 2019-03-29 | $130.93M 10-Q · filed 2020-05-05 | |||
| 2018-12-28 | $414.97M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |